CLEC4C: C-type lectin domain family 4 member C
Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CLEC4C, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Litifilimab | Phase 3 | Biogen | Antibody | InhibitorC-type lectin domain family 4 member C inhibitor | 5 |
- Systemic lupus erythematosus0.40
- Cutaneous lupus erythematosus0.36
- Chronic cutaneous lupus erythematosus0.18
- Congenital anomaly of cardiovascular system0.16
- Immunoglobulin G4-related sclerosing disease0.05
- Chronic obstructive pulmonary disease0.04
- CD4+/CD56+ hematodermic neoplasm0.04
- Non-small cell lung carcinoma0.04
- IgG4-related ophthalmic disorder0.03
- Colonic neoplasm0.03
- Malignant colon neoplasm0.03
- Hepatocellular carcinoma0.03
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2176855, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q8WTT0, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets